Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C90573
http://purl.obolibrary.org/obo/NCIT_C90573
|
|---|---|
| Preferred Name | JAK2 Inhibitor XL019 |
| Definitions |
An orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2) with potential antineoplastic activity. XL019 inhibits the activation of JAK2 as well as the mutated form JAK2V617F, which may result in the inhibition of the JAK-STAT signaling pathway and may induce apoptosis. The JAK2 mutated form JAK2V617F has a valine-to-phenylalanine modification at position 617 and plays a key role in tumor cell proliferation and survival.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2) with potential antineoplastic activity. XL019 inhibits the activation of JAK2 as well as the mutated form JAK2V617F, which may result in the inhibition of the JAK-STAT signaling pathway and may induce apoptosis. The JAK2 mutated form JAK2V617F has a valine-to-phenylalanine modification at position 617 and plays a key role in tumor cell proliferation and survival. |
|---|---|
| prefLabel | JAK2 Inhibitor XL019
|
| label | JAK2 Inhibitor XL019
|
| NCI_META_CUI | CL416257
|
| PDQ_Closed_Trial_Search_ID | 667451
|
| code | C90573
|
| Has_Target | |
| prefixIRI | NCIT:C90573
|
| in_subset |
See more
See less
|
| Display_Name | JAK2 Inhibitor XL019
|
| Preferred_Name | JAK2 Inhibitor XL019
|
| FDA_UNII_Code | 4L1AM42NVA
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | JAK2 Inhibitor XL019
|
| CAS_Registry | 945755-56-6
|
| NCI_Drug_Dictionary_ID | 667451
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 667451
|
| Semantic_Type | Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |